{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T09:18:36Z","timestamp":1778923116884,"version":"3.51.4"},"reference-count":38,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":599,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01 CA213140"],"award-info":[{"award-number":["U01 CA213140"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["U01 CA213140"],"award-info":[{"award-number":["U01 CA213140"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.jtct.2021.06.014","type":"journal-article","created":{"date-parts":[[2021,6,19]],"date-time":"2021-06-19T01:10:17Z","timestamp":1624065017000},"page":"840.e1-840.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Reduction in Late Mortality Among Patients With Multiple Myeloma Treated With Autologous Peripheral Blood Stem Cell Transplantation\u2014A Blood or Marrow Transplant Survivor Study Report"],"prefix":"10.1016","volume":"27","author":[{"given":"Smith","family":"Giri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanjun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsey","family":"Hageman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"Richman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liton","family":"Francisco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy","family":"Landier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciano","family":"Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna","family":"Murdaugh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F Lennie","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J.","family":"Weisdorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen J.","family":"Forman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mukta","family":"Arora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saro H.","family":"Armenian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Smita","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jtct.2021.06.014_bib0001","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.jtct.2021.06.014_bib0002","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/bloodadvances.2016002493","article-title":"Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States","volume":"1","author":"Costa","year":"2017","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.jtct.2021.06.014_bib0003","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41408-018-0155-7","article-title":"Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma \u2014 an IMWG Research Project","volume":"8","author":"Usmani","year":"2018","journal-title":"Blood Cancer J"},{"issue":"14","key":"10.1016\/j.jtct.2021.06.014_bib0004","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1200\/JCO.18.02096","article-title":"Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline","volume":"37","author":"Mikhael","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jtct.2021.06.014_bib0005","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome","volume":"335","author":"Attal","year":"1996","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.jtct.2021.06.014_bib0006","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.jtct.2021.06.014_bib0007","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jtct.2021.06.014_bib0008","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/annonc\/mdw606","article-title":"Second primary malignancies in multiple myeloma: an overview and IMWG consensus","volume":"28","author":"Musto","year":"2017","journal-title":"Ann Oncol"},{"issue":"29","key":"10.1016\/j.jtct.2021.06.014_bib0009","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis","volume":"35","author":"McCarthy","year":"2017","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.jtct.2021.06.014_bib0010","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1001\/jamaoncol.2016.0855","article-title":"Physiologic frailty in nonelderly hematopoietic cell transplantation patients: results from the Bone Marrow Transplant Survivor Study","volume":"2","author":"Arora","year":"2016","journal-title":"JAMA Oncol"},{"issue":"14","key":"10.1016\/j.jtct.2021.06.014_bib0011","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1002\/cncr.32941","article-title":"Morbidity burden in survivors of multiple myeloma who underwent autologous transplantation: A Bone Marrow Transplantation Survivor Study","volume":"126","author":"Arora","year":"2020","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.jtct.2021.06.014_bib0012","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1182\/blood-2005-01-0035","article-title":"Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study","volume":"105","author":"Bhatia","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.06.014_bib0013","article-title":"Trends in cause of death among patients with multiple myeloma in Puerto Rico and the United States SEER population, 1987-2013","author":"Castaneda-Avila","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jtct.2021.06.014_bib0014","unstructured":"2020. https:\/\/www.cdc.gov\/nchs\/ndi\/index.html. Accessed January 17, 2021."},{"key":"10.1016\/j.jtct.2021.06.014_bib0015","unstructured":"2020. http:\/\/www.accurint.com\/index.html. Accessed January 17, 2021."},{"issue":"4","key":"10.1016\/j.jtct.2021.06.014_bib0016","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.jtct.2021.06.014_bib0017","unstructured":"Centers for Disease Control and Prevention https:\/\/wonder.cdc.gov\/mortSQL.html. Accessed January 17, 2021."},{"key":"10.1016\/j.jtct.2021.06.014_bib0018","doi-asserted-by":"crossref","unstructured":"Vandenbroucke JP. A shortcut method for calculating the 95 per cent confidence interval of the standardized mortality ratio. Am J Epidemiol.2020;115(2):303-304.","DOI":"10.1093\/oxfordjournals.aje.a113306"},{"issue":"7","key":"10.1016\/j.jtct.2021.06.014_bib0019","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1182\/bloodadvances.2016003269","article-title":"Cardiac and renal complications of carfilzomib in patients with multiple myeloma","volume":"1","author":"Dimopoulos","year":"2017","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.jtct.2021.06.014_bib0020","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3324\/haematol.2014.107714","article-title":"Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients","volume":"100","author":"Blimark","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2021.06.014_bib0021","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2016.07.025","article-title":"Infection risk with immunomodulatory and proteasome inhibitor-based therapies across treatment phases for multiple myeloma: a systematic review and meta-analysis","volume":"67","author":"Teh","year":"2016","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.jtct.2021.06.014_bib0022","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S1470-2045(13)70609-0","article-title":"Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data","volume":"15","author":"Palumbo","year":"2014","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.jtct.2021.06.014_bib0023","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.bbmt.2007.06.003","article-title":"Late effects in survivors of Hodgkin and non-Hodgkin lymphoma treated with autologous hematopoietic cell transplantation: a report from the bone marrow transplant survivor study","volume":"13","author":"Majhail","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2021.06.014_bib0024","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/bjh.15426","article-title":"Second primary malignancy after multiple myeloma-population trends and cause-specific mortality","volume":"182","author":"Costa","year":"2018","journal-title":"Br J Haematol"},{"issue":"16","key":"10.1016\/j.jtct.2021.06.014_bib0025","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2012.46.3323","article-title":"Multiple myeloma treatment transformed: a population-based study of changes in initial management approaches in the United States","volume":"31","author":"Warren","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jtct.2021.06.014_bib0026","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1182\/blood.V99.3.731","volume":"99","author":"Moreau","year":"2002","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jtct.2021.06.014_bib0027","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.3324\/haematol.2018.194118","article-title":"Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR","volume":"103","author":"Spencer","year":"2018","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.jtct.2021.06.014_bib0028","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.3324\/haematol.2018.194282","article-title":"Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX","volume":"103","author":"Dimopoulos","year":"2018","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.jtct.2021.06.014_bib0029","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.jtct.2021.06.014_bib0030","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.jtct.2021.06.014_bib0031","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2021.06.014_bib0032","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2016.07.025","article-title":"Infection risk with immunomodulatory and proteasome inhibitor\u2013based therapies across treatment phases for multiple myeloma: A systematic review and meta-analysis","volume":"67","author":"Teh","year":"2016","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.jtct.2021.06.014_bib0033","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"issue":"22","key":"10.1016\/j.jtct.2021.06.014_bib0034","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jtct.2021.06.014_bib0035","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.jtct.2021.06.014_bib0036","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.jtct.2021.06.014_bib0037","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.jtct.2021.06.014_bib0038","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.3117.3117","article-title":"Therapy Related MDS\/AML In Multiple Myeloma Patients In The Era Of Novel Agents","volume":"122","author":"A Gertz","year":"2013","journal-title":"Blood"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636721009982?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636721009982?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T09:00:17Z","timestamp":1778922017000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636721009982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S2666636721009982"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2021.06.014","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reduction in Late Mortality Among Patients With Multiple Myeloma Treated With Autologous Peripheral Blood Stem Cell Transplantation\u2014A Blood or Marrow Transplant Survivor Study Report","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2021.06.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}